Alnylam Opens ‘Advocacy for Impact’ Grant Program Supporting FAP, Like Patient Groups

Alnylam Pharmaceuticals has opened its second annual competitive grants program, supporting patient advocacy projects worldwide that aim to address the unmet and diverse needs of ATTR amyloidosis, a group of conditions that include familial amyloid polyneuropathy (FAP). Applications for the program, called Advocacy for Impact, are now open and can…